Expression profile of standard and variants forms of CD44 related to prostate cancer behavior

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMOURA, Caio M.
dc.contributor.authorPONTES JR., Jose
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorVIANA, Nayara I.
dc.contributor.authorMORAIS, Denis R.
dc.contributor.authorDIP, Nelson
dc.contributor.authorKATZ, Betina
dc.contributor.authorSROUGI, Miguel
dc.contributor.authorLEITE, Katia R. M.
dc.date.accessioned2015-10-26T16:23:56Z
dc.date.available2015-10-26T16:23:56Z
dc.date.issued2015
dc.description.abstractCD44 is a transmembrane glycoprotein and is regarded as a potential marker in various tumors. The aim of our study was to analyze the expression of the standard form of CD44 (CD44s) and its isoforms in localized prostate cancer (PCa), and to correlate these data with the classical prognostic factors and biochemical recurrence. Ninety-four surgical specimens were analyzed in this study. The expression levels of CD44s and all its 9 variants were analyzed by quantitative real time PCR (qRT-PCR). The control group consisted of 14 specimens from patients with benign prostatic hyperplasia. We correlated all the expression profiles with biochemical recurrence, as defined by a PSA > 0.4 ng/mL in a mean follow-up period of 53.3 months. In PCa, CD44s was underexpressed and all the other isoforms were overexpressed. The mean expression level of most variants was higher in patients who had not recurred, and a higher expression of CD44v2 independently correlated with a better recurrence-free survival rate (p=0.045). This variant was also underexpressed in metastatic PCa cell lines. There was no correlation between the expression levels of any of the CD44 isoforms and the classical prognostic factors. We here demonstrated that PCa cases are characterized by a change in the expression of CD44, with a loss of CD44s and an overexpression of all the other CD44 variants. However, during cancer progression we found a loss of expression of all CD44 variants, and a correlation between higher expression of CD44v2 and a better recurrence-free survival rate. The understanding of the CD44 expression patterns in PCa could contribute to its use as a new prognostic marker.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [2010/51427-6]
dc.identifier.citationINTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, v.30, n.1, p.E49-E55, 2015
dc.identifier.doi10.5301/jbm.5000091
dc.identifier.eissn1724-6008
dc.identifier.issn0393-6155
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/11518
dc.language.isoeng
dc.publisherWICHTIG EDITORE
dc.relation.ispartofInternational Journal of Biological Markers
dc.rightsrestrictedAccess
dc.rights.holderCopyright WICHTIG EDITORE
dc.subjectCD44
dc.subjectIsoforms
dc.subjectProstate cancer
dc.subject.othermetastasis
dc.subject.otherhypermethylation
dc.subject.othercarcinoma
dc.subject.otherprognosis
dc.subject.otherinvasion
dc.subject.otherantigen
dc.subject.othercells
dc.subject.othergene
dc.subject.othermen
dc.subject.wosBiotechnology & Applied Microbiology
dc.subject.wosOncology
dc.titleExpression profile of standard and variants forms of CD44 related to prostate cancer behavior
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus13
hcfmusp.contributor.author-fmusphcCAIO MARTINS MOURA
hcfmusp.contributor.author-fmusphcJOSE PONTES JUNIOR
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcNAYARA IZABEL VIANA MOURA
hcfmusp.contributor.author-fmusphcDENIS REIS MORAIS
hcfmusp.contributor.author-fmusphcNELSON GASPAR DIP JUNIOR
hcfmusp.contributor.author-fmusphcBETINA STIFELMAN KATZ
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.description.beginpageE49
hcfmusp.description.endpageE55
hcfmusp.description.issue1
hcfmusp.description.volume30
hcfmusp.origemWOS
hcfmusp.origem.pubmed24832177
hcfmusp.origem.scopus2-s2.0-84930068448
hcfmusp.origem.wosWOS:000356665100006
hcfmusp.publisher.cityMILAN
hcfmusp.publisher.countryITALY
hcfmusp.relation.referenceAl-Maghrabi J, 2012, ANTICANCER RES, V32, P3455
hcfmusp.relation.referenceBorland G, 1998, IMMUNOLOGY, V93, P139
hcfmusp.relation.referenceCARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215
hcfmusp.relation.referenceCATALONA WJ, 1994, J UROLOGY, V151, P1283
hcfmusp.relation.referenceGhatak S, 2010, J BIOL CHEM, V285, P19821, DOI 10.1074/jbc.M110.104273
hcfmusp.relation.referenceGotoda T, 2000, GUT, V46, P14, DOI 10.1136/gut.46.1.14
hcfmusp.relation.referenceIczkowski Kenneth A, 2010, Am J Transl Res, V3, P1
hcfmusp.relation.referenceIczkowski KA, 2003, ANTICANCER RES, V23, P3129
hcfmusp.relation.referenceKito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124
hcfmusp.relation.referenceKrishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078
hcfmusp.relation.referenceLou W, 1999, CANCER RES, V59, P2329
hcfmusp.relation.referenceMisra S, 2011, FEBS J, V278, P1429, DOI 10.1111/j.1742-4658.2011.08071.x
hcfmusp.relation.referenceNaor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574
hcfmusp.relation.referenceOmara-Opyene AL, 2004, LAB INVEST, V84, P894, DOI 10.1038/labinvest.3700112
hcfmusp.relation.referenceOmran OM, 2012, ULTRASTRUCT PATHOL, V36, P145, DOI 10.3109/01913123.2011.651522
hcfmusp.relation.referenceOrian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024
hcfmusp.relation.referenceRobbins EW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-260
hcfmusp.relation.referenceSiegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
hcfmusp.relation.referenceTei H, 2014, UROL ONCOL, V13, P1078
hcfmusp.relation.referenceVerkaik NS, 2000, LAB INVEST, V80, P1291, DOI 10.1038/labinvest.3780137
hcfmusp.relation.referenceYang K, 2009, INT J CLIN EXP PATHO, V2, P361
hcfmusp.relation.referenceZoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationbc28b381-6994-4655-9f48-9bc7136e4db9
relation.isAuthorOfPublication8f302d44-7ff3-4af9-bb58-76bce498a3a6
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublication32f63bee-3f86-4e8d-b307-f29f080dd7b4
relation.isAuthorOfPublication7af4bd17-a1d2-4c42-a4af-e0919576a464
relation.isAuthorOfPublication7b98028d-1464-41f7-b473-7326a36a8d3c
relation.isAuthorOfPublication01d7a5da-3983-420d-b86f-291cd9d6378b
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication.latestForDiscoverybc28b381-6994-4655-9f48-9bc7136e4db9
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MOURA_Expression_profile_of_standard_and_variants_forms_of_2015.PDF
Tamanho:
223.79 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03